Haematological malignancies

Gene: SH2B3

Amber List (moderate evidence)

SH2B3 (SH2B adaptor protein 3, Ensemblv90)
EnsemblGeneIds (GRCh38): ENSG00000111252
EnsemblGeneIds (GRCh37): ENSG00000111252
OMIM: 605093, ClinGen, DECIPHER
SH2B3 is in 1 panel

2 reviews

Ain Roesley (Victorian Clinical Genetics Services)

Green List (high evidence)

PMID:37206266
2x families
- hom missense variant Val402Met:
functional performed on patient's fibroblasts demonstrated increased basal pSTAT5, pSTAT3 and increased pJAK2 + pSTAT5 after stimulation with IL-3, GH, GM-CSF and EPO

- hom fs Arg148Profs*40
functional performed in zebrafish demonstrated increased number of macrophages and thrombocytes

PMID:23908464;
1 fam with 2 affecteds with dev delay + autoimmunity + (1x) ALL, hom for Asp231Gly fs*3

PMID:38152053;
JMML cohort - 2x hom missense + 2x het PTCs
Created: 1 Feb 2024, 11:29 a.m. | Last Modified: 1 Feb 2024, 11:29 a.m.
Panel Version: 1.1502

Mode of inheritance
BIALLELIC, autosomal or pseudoautosomal

Phenotypes
Myeloproliferation and multi-organ autoimmunity; juvenile myelomonocytic leukemia MONDO:001190, SH2B3-related

Publications

Variants in this GENE are reported as part of current diagnostic practice

Zornitza Stark (Victorian Clinical Genetics Services)

Green List (high evidence)

Germline variants reported in association with increased risk for haematological malignancies.
Created: 24 Jul 2020, 12:24 p.m. | Last Modified: 24 Jul 2020, 12:24 p.m.
Panel Version: 0.3496

Mode of inheritance
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted

Phenotypes
Predisposition to haematological malignancies

Publications

Details

Mode of Inheritance
BOTH monoallelic and biallelic, autosomal or pseudoautosomal
Sources
  • Expert Review Amber
  • Curated sources
  • Victorian Clinical Genetics Services
Phenotypes
  • Autoimmunity
  • No other known cancer risks
  • Class: familial predisp to leukaemia (typ AD)
  • SH2B3-related familial ALL
  • ALL
OMIM
605093
ClinGen
SH2B3
DECIPHER
SH2B3
Clinvar variants
Variants in SH2B3
Penetrance
None
Publications
Panels with this gene

History Filter Activity

Note: This information shows the history of the gene symbol, not the gene entity. Where the gene symbol for a gene has changed, this history may reference a different gene to the entry you are currently viewing.
19 Mar 2026, Gel status: 2

Entity classified by Genomics England curator

Bryony Thompson (Royal Melbourne Hospital)

Gene: sh2b3 has been classified as Amber List (Moderate Evidence).

19 Mar 2026, Gel status: 3

Entity classified by Genomics England curator

Bryony Thompson (Royal Melbourne Hospital)

Gene: sh2b3 has been classified as Green List (High Evidence).

19 Mar 2026, Gel status: 3

Set mode of inheritance

Bryony Thompson (Royal Melbourne Hospital)

Mode of inheritance for gene: SH2B3 was changed from BIALLELIC, autosomal or pseudoautosomal to BOTH monoallelic and biallelic, autosomal or pseudoautosomal

19 Mar 2026, Gel status: 3

Entity classified by Genomics England curator

Bryony Thompson (Royal Melbourne Hospital)

Gene: sh2b3 has been classified as Green List (High Evidence).

19 Mar 2026, Gel status: 2

Set publications

Bryony Thompson (Royal Melbourne Hospital)

Publications for gene: SH2B3 were set to 23908464; 27913496; 39316992; 27881370; 28484264

7 Feb 2026, Gel status: 2

Created, Added New Source, Set mode of inheritance, Set publications, Set Phenotypes

Bryony Thompson (Royal Melbourne Hospital)

gene: SH2B3 was added gene: SH2B3 was added to Haematological malignancies cancer susceptibility. Sources: Curated sources,Expert Review Amber Mode of inheritance for gene: SH2B3 was set to BIALLELIC, autosomal or pseudoautosomal Publications for gene: SH2B3 were set to 23908464; 27913496; 39316992; 27881370; 28484264 Phenotypes for gene: SH2B3 were set to Autoimmunity; No other known cancer risks; Class: familial predisp to leukaemia (typ AD); SH2B3-related familial ALL; ALL